Company intelligence / Profile preview
OncoPrecision
New York, New York, United Statesoncoprecision.bio ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has developed Patient Micro Avatar technology that recreates cancer patients' disease ex-vivo and evaluates drug responses within one week. ONC001 (CD64-ADC) has demonstrated "remarkable efficacy and tolerability across multiple in vivo models."
- Therapeutic areas
- OncologyHematology
- Modalities
- Antibody-drug conjugateBispecific monoclonal antibody
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Leading cancer centers in North and South America for clinical validation studiesactive collaborations with pharmaceutical companies for drug development
Beyond the preview
Go deeper on OncoPrecision.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OncoPrecision.